Antibiotic resistance, biofilm formation, and biofilm-associated genes among Stenotrophomonas maltophilia clinical isolates.


Journal

BMC research notes
ISSN: 1756-0500
Titre abrégé: BMC Res Notes
Pays: England
ID NLM: 101462768

Informations de publication

Date de publication:
20 Apr 2021
Historique:
received: 05 11 2020
accepted: 13 04 2021
entrez: 21 4 2021
pubmed: 22 4 2021
medline: 15 5 2021
Statut: epublish

Résumé

The purpose of the present study was to investigate the antimicrobial susceptibility pattern, biofilm production, and the presence of biofilm genes among the S. maltophilia clinical isolates. A total of 85 clinical isolates of S. maltophilia were collected from patients referred to several hospitals. Susceptibility to antibiotics was investigated by disc diffusion method according to the guidelines of the Clinical and Laboratory Standards Institute (CLSI). By the crystal violet staining method, the capability of biofilm formation was examined. The genes associated with biofilm production were investigated by the PCR-sequencing techniques. All isolates were resistant to doripenem, imipenem, and meropenem. Minocycline, trimethoprim/sulfamethoxazole and levofloxacin exhibited the highest susceptibility of 100%, 97.65%, and 95.29%, respectively. The results of crystal violet staining assay showed that all isolates (100%) form biofilm. Moreover, 24 (28.23%), 32 (37.65%), and 29 (34.12%) of isolates were categorized as weak, moderate, and strong biofilm producers, respectively. Biofilm genes including rpfF, spgM and rmlA had an overall prevalence of 89.41% (76/85), 100% (85/85) and 84.71% (72/85), respectively. Rational prescribing of antibiotics and implementation of infection control protocols are necessary to prevent further infection and development of antimicrobial resistance. Combination strategies based on the appropriate antibiotics along with anti-biofilm agents can also be selected to eliminate biofilm-associated infections.

Identifiants

pubmed: 33879237
doi: 10.1186/s13104-021-05567-y
pii: 10.1186/s13104-021-05567-y
pmc: PMC8059177
doi:

Substances chimiques

Anti-Bacterial Agents 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

151

Références

APMIS. 2007 Aug;115(8):891-9
pubmed: 17696944
mBio. 2017 Jun 20;8(3):
pubmed: 28634237
Expert Rev Anti Infect Ther. 2014 Jan;12(1):1-4
pubmed: 24308713
Front Cell Infect Microbiol. 2020 Feb 18;10:50
pubmed: 32133303
Expert Rev Anti Infect Ther. 2019 Nov;17(11):877-893
pubmed: 31658838
J Bacteriol. 2007 Jul;189(13):4964-8
pubmed: 17468254
Antimicrob Agents Chemother. 2010 Jun;54(6):2735-7
pubmed: 20368399
Front Microbiol. 2018 Apr 26;9:806
pubmed: 29755435
Front Microbiol. 2017 Nov 30;8:2276
pubmed: 29250041
BMC Microbiol. 2010 Apr 07;10:102
pubmed: 20374629
Front Cell Infect Microbiol. 2020 Aug 11;10:411
pubmed: 32850503
PLoS One. 2016 Oct 31;11(10):e0165660
pubmed: 27798695
Antibiotics (Basel). 2020 Feb 03;9(2):
pubmed: 32028684
Sci Rep. 2017 Jul 5;7(1):4665
pubmed: 28680041
Front Microbiol. 2015 Sep 16;6:951
pubmed: 26441885
Sci Rep. 2016 Jul 13;6:29701
pubmed: 27405358
Int J Antimicrob Agents. 2010 Apr;35(4):322-32
pubmed: 20149602
Int J Antimicrob Agents. 2010 Feb;35(2):126-30
pubmed: 19926255
J Bacteriol. 2006 Apr;188(8):3116-20
pubmed: 16585771
Open Forum Infect Dis. 2019 Mar 15;6(Suppl 1):S34-S46
pubmed: 30895213
Med Mal Infect. 2020 May;50(3):305-307
pubmed: 32014291
J Med Microbiol. 2014 Nov;63(Pt 11):1524-1530
pubmed: 25165124
Infect Immun. 2003 Jun;71(6):3068-75
pubmed: 12761084
Microb Drug Resist. 2016 Dec;22(8):688-695
pubmed: 27007167
mBio. 2019 Jul 2;10(4):
pubmed: 31266860
PLoS One. 2014 Oct 06;9(10):e108409
pubmed: 25285537
J Glob Infect Dis. 2011 Jul;3(3):254-8
pubmed: 21887057
Infect Chemother. 2016 Dec;48(4):285-293
pubmed: 28032486
Antibiotics (Basel). 2020 Jan 02;9(1):
pubmed: 31906465
Afr Health Sci. 2020 Mar;20(1):168-181
pubmed: 33402905
Front Microbiol. 2019 May 29;10:1191
pubmed: 31191502
Clin Neurol Neurosurg. 2013 Sep;115(9):1709-15
pubmed: 23611735
Clin Microbiol Rev. 2012 Jan;25(1):2-41
pubmed: 22232370
J Med Microbiol. 2017 Aug;66(8):1102-1109
pubmed: 28771141
FEMS Microbiol Lett. 2008 Oct;287(1):41-7
pubmed: 18681866
BMC Microbiol. 2020 Sep 29;20(1):294
pubmed: 32993493

Auteurs

Narjess Bostanghadiri (N)

Department of Microbiology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.

Abdollah Ardebili (A)

Laboratory Sciences Research Center, Golestan University of Medical Sciences, Gorgan, Iran.
Department of Microbiology, Faculty of Medicine, Golestan University of Medical Sciences, Gorgan, Iran.

Zohreh Ghalavand (Z)

Department of Microbiology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Samane Teymouri (S)

Department of Microbiology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.

Mahsa Mirzarazi (M)

Student Research Committee, Department of Medical Biotechnology, School of Advanced Technologies in Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Mehdi Goudarzi (M)

Department of Microbiology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Ehsan Ghasemi (E)

Abadan School of Medical Sciences, Abadan, Iran.

Ali Hashemi (A)

Department of Microbiology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran. ali.hashemi@sbmu.ac.ir.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH